Jasani acquires 1.11 lakh shares in Hemo Organic, holding rises to 6.84%

1 min read | Published on 25 Sept 2026, 05:41 PM |Updated on 25 Sept 2026, 05:41 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Dharmendrabhai Becharbhai Jasani acquired 1,11,341 equity shares of Hemo Organic Limited on September 7, 2026.
The on-market purchase increased his combined holding with PACs to 2,37,414 shares, or 6.84% of voting capital.
The acquirer is not part of the promoter group; PACs include family members and a private trust.
Total diluted capital stands at 68,65,900 shares, resulting in a 3.45% diluted holding post-acquisition.

*this image is generated using AI for illustrative purposes only.

Dharmendrabhai Becharbhai Jasani acquired 1,11,341 equity shares of Hemo Organic Limited through an on-market transaction on September 7, 2026. This acquisition increased his combined holding with persons acting in concert to 6.84% of the company's voting capital.

The disclosure was filed with BSE Limited under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Jasani is not part of the promoter or promoter group of Hemo Organic Limited.

Acquisition details

The acquirer purchased shares directly in the open market. The Persons Acting in Concert (PACs) include Jasani Family Private Trust, Heemaben Makadia, Ayush Dharmendrabhai Jasani, and Ketanaben Jasani. No shares were acquired by the PAC entities during this specific transaction period.

Metric	Before Acquisition	Acquisition	After Acquisition
Number of Shares	1,26,073	1,11,341	2,37,414
% of Voting Capital	3.63%	3.21%	6.84%
% of Diluted Capital	1.83%	1.62%	3.45%

Shareholding structure

Prior to this transaction, the aggregate holding of Jasani and his PACs stood at 1,26,073 shares, representing 3.63% of the total voting capital. Following the acquisition, the total holding rose to 2,37,414 shares.

The company's total equity share capital remained unchanged at 34,65,900 equity shares of ₹10 each, aggregating to ₹3,46,59,000. The total diluted share capital, assuming full conversion of outstanding convertible securities, stands at 68,65,900 equity shares of ₹10 each, aggregating to ₹6,86,59,000.

What the numbers show

The acquisition represents a significant single-step increase in ownership, adding 3.21% to the voting capital stake. The gap between the percentage of voting capital (6.84%) and diluted capital (3.45%) post-acquisition highlights the presence of substantial convertible instruments or warrants outstanding in Hemo Organic Limited, which dilute the effective equity ownership percentage relative to the current voting power.

Will Dharmendrabhai Jasani's holding exceeding the 5% threshold trigger further mandatory disclosures or potential takeover bid obligations under SEBI regulations?

How might the significant dilution gap between voting capital (6.84%) and diluted capital (3.45%) impact Hemo Organic Limited's future equity fundraising strategies?

Does the substantial increase in Jasani's stake signal a strategic move toward acquiring board representation or influencing corporate governance at Hemo Organic?

Hemo Organic cancels board meeting to consider fund raising

1 min read | Published on 19 Sept 2026, 06:49 PM |Updated on 21 Sept 2026, 06:55 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Hemo Organic Ltd cancels board meeting scheduled for September 23, 2026
Cancellation due to unavoidable reasons, intimated on September 21, 2026
Meeting was to consider fund raising via QIP, preferential allotment, or rights issue
Trading window remains closed per SEBI insider trading regulations

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited has cancelled its board of directors meeting scheduled for September 23, 2026. The company cited unavoidable reasons for the cancellation in an intimation to BSE Limited dated September 21, 2026.

The cancelled meeting was originally convened to consider proposals for raising funds through various permissible modes, including qualified institutions placement (QIP) and preferential allotment. The board had planned to approve the issuance of equity shares or convertible securities.

Previous Agenda Details

The earlier agenda included considering the issuance of equity shares and convertible securities, including convertible warrants. The company was exploring options to raise funds in one or more tranches through:

Preferential allotment
Private placement
Qualified institutions placement (QIP)
Rights issue
Further public issue

These actions required statutory approvals and consent from members. The board was also set to consider any ancillary actions required for such fund raising.

Regulatory Compliance

The initial disclosure regarding the meeting was made pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ayush Dharmendrabhai Jasani, Chairman and Additional Director, signed the intimation letter addressed to BSE Limited.

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window had been closed starting from business closing hours on September 19, 2026. This restriction continues until 48 hours after the conclusion of the board meeting, although the meeting itself is now cancelled.

What specific operational or regulatory hurdles caused the cancellation of the board meeting, and when might a rescheduled date be announced?

How will the delay in finalizing fund-raising mechanisms like QIP or preferential allotment impact Hemo Organic's current liquidity and ongoing project timelines?

Does the indefinite closure of the trading window due to the cancelled meeting create prolonged uncertainty for retail investors holding Hemo Organic shares?